RxDoctor Payments Data

Joshua Schiffer, MD

Infectious Disease · Seattle, WANPI 1639114929

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,289 of the $14,289 with a category attached, or 100.0%. GSK accounts for 81.2% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2023 at $8,034 and has fallen 55.5% since, to $3,575 in 2024. Among infectious disease clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,289in general payments, 2019–2025

Across 4 payments — averaging $3572.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$12K
  • Seagen Inc.$3K
$275,618in research payments, 2019–2025

Across 2 payments — averaging $137,809 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$276K

What the payments were for

  • Consulting fees$14,289100%

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK3$11,609
Seagen Inc.1$2,680

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,289 in reported general payments places this provider in the 90th percentile of 186 infectious disease providers in Washington.

See all infectious disease providers in Washington

Medicare billing

Part B allowed, 2024
$5,728
Medicare patients
25
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →